Proper induction of Th1 immunity is required for effective immunotherapy of bladder cancer with the bacillus Calmette-Guérin (BCG).
Interleukin-10 (IL-10) downregulates the Th1 immune response and is associated with BCG therapy failure. We evaluated BCG plus IL-10 blocking antibodies and found that this combination therapy induces enhanced Th1 immune responses and anti-bladder cancer immunity in preclinical animal models.
Written by:
Luo Y. Are you the author?
Department of Urology; University of Iowa; Iowa City, IA USA
Reference: Oncoimmunology. 2012 Oct 1;1(7):1183-1185
PubMed Abstract
PMID: 23170273
